Blindness is one of the most severe injuries alleged in connection with GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza. A growing number of patients report sudden vision loss, often diagnosed as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
Some research has indicated that patients prescribed semaglutide may have a greater chance of a Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) diagnosis. Recently, there is more data showing there is at a minimum an association between GLP-1 prescriptions and NAION. However, there isn’t appropriate clinical research to definitively prove that semaglutide causes NAION. The primary reason for this is because type 2 diabetes is a risk factor associated with NAION and various eye medical issues.
In 2024 there was a study from Mass Eye and Ear set forth in JAMA Ophthalmology. Patients prescribed semaglutide had a four times greater chance of a NAION diagnosis compared to patients prescribed other diabetes drug scripts. Among obese people with a semaglutide script, the risk increased to more than seven times. A new study in the Europe continent suggests an important increase in NAION among patients with semaglutide prescription over a long period of time who also had diabetes. The European Medicines Agency is conducting a risk assessment and suggest the need for label warnings. Currently there is an MDL in Federal Court where litigants may pursue an Ozempic lawsuit. People may also file a GLP-1 blindness lawsuit in State Court in New Jersey in the Multicounty litigation. Because NAION can cause permanent, irreversible blindness, these claims are treated as a separate, high-severity injury category in GLP-1 litigation and are now handled in their own federal MDL.
What Is NAION?
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a condition caused by reduced blood flow to the optic nerve.
Key characteristics:
- sudden, painless vision loss
- often occurs upon waking
- commonly affects one eye
- damage is frequently permanent
- no proven treatment to restore lost vision
- NAION is considered a medical emergency.
Loss of vision resulting from NAION is an untreatable issue that may cause permanent blindness. Vision loss from NAION is normally sudden, and usually only realized when a patient awakens in the am and realizes vision loss in one eye. Patients with a confirmed NAION diagnosis have blurred or darkened vision which may obstruct their field of view. Victims may also experience decrease of color vision as well as decrease of contrast in vision. 15% of patients suffer with NAION in one eye are also diagnosed with NAION it their other eye. Most people with a NAION diagnosis, will not have improved vision over time. Certain victims will endure their vision getting progressively worse subsequent to initial loss of vision.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a severe, scary and generally irreversible condition of the eye (sometimes referred to as “eye stroke”). NAION can lead to abrupt, loss of vision in one eye which is painless. NAION constitutes a severe eye condition that leads to sudden, usually painless, loss of vision or blurry vision as a result of low blood flow to the optic nerve. NAION may manifest itself without warning, literally, often within hours. NAION occurs if blood flow to the optic nerve is blocked, reduced or lowered, which may cause blindness. The optic nerve will fail to regenerate. NAION causes optic nerve damage and unexplained loss of vision. Poonja S, Chen JJ. Re-examining the putative association between GLP-1 receptor agonists and nonarthritic anterior ischemic optic neuropathy. Ann Eye Sci 2025;10:5–5. [Google Scholar] NAION is the 2nd biggest cause of vision loss linked to optic nerve damage after glaucoma.
Nonetheless, many people with a GLP-1 script are oblivious to it before their NAION diagnosis. Such vision loss usually happens overnight. NAION could also result in a change in color perception as well as progressive vision loss. NAION is veryproblematic because NAION cannot be managed or improved with the best medical intervention. The American Academy of Ophthalmology determined that NAION is the most ubiquitous cause of acute optic nerve damage in victims greater than 49 years of age. Even though NAION frequently, occurs, numerous aspects of it, remains unknown or perhaps unproven. NAION’s pathogenesis and worthwhile treatments remain relatively unknown. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology 2024;142:732–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
Am I eligible to File a Lawsuit for Ozempic Blindness?
A litigant may qualify to file an ozempic lawsuit if the person meets the Ozempic lawsuit criteria:
- Victim prescribed GLP-1 drug.
- Victim has sudden loss of vision, optic nerve damage, or a confirmed NAION diagnosis.
- Person has medical reports which indicate both a diagnosis as well as medical treatment.
- Person has not signed a waiver of liability or already reached a written settlement of their possible claim for damages.
- Victims who have have received partial compensation could possibly still qualify for an ozempic payout and receive compensation.
Vision Loss Reported After GLP-1 Drug Use
Reported symptoms include:
- sudden blindness in one eye
- partial vision loss or dark spots
- blurred or dim vision
- loss of peripheral vision
- permanent visual field defects
Many patients report no prior warning signs.
How GLP-1 Drugs May Contribute to NAION
Medical experts are evaluating several mechanisms:
A. Blood Pressure & Nocturnal Hypotension
GLP-1 drugs may lower blood pressure, especially overnight — a known NAION risk factor.
B. Dehydration & Volume Depletion
Vomiting and reduced fluid intake can decrease optic nerve perfusion.
C. Rapid Metabolic Changes
Rapid weight loss and vascular changes may increase ischemic vulnerability.
Who Is at Higher Risk?
Risk factors include:
- diabetes
- hypertension
- sleep apnea
- cardiovascular disease
- smoking history
- age 40+
- “crowded” optic nerve anatomy
Many GLP-1 users fall into multiple overlapping risk categories.
Why Blindness Claims Are Treated Separately
Vision loss cases differ because:
- blindness is often permanent
- damages are lifelong
- causation analysis is ophthalmologic
- expert testimony differs from GI cases
As a result, NAION cases are not grouped with gastroparesis or GI MDLs.
➡️ MDL overview: MDL
Evidence Used in NAION Lawsuits
Strong claims often include:
- ophthalmology or neuro-ophthalmology records
- OCT imaging and fundus photography
- visual field testing
- ER or urgent ophthalmology visits
- documented sudden onset
- GLP-1 prescription history
What are some signs of NAION?
- Abrupt loss of vision: Typically occurs within hours or even days.
- Unilateral loss of vision: Vision loss in one eye.
- Blurriness: Blurry vision.
- Cloudiness: Dim vision, blurry or perhaps even gray.
- Vision loss (Central): Visual field in the center may be affected, causing issues reading or even perhaps viewing details.
- Peripheral vision could still be preserved: Even though central vision may be impaired, peripheral vision could still be good.
- No pain or redness in eye: The opposite of other eye issues, NAION rarely leads to pain or redness.
- Could coincide with other complications: Certain people could have dizziness, headaches, or even nausea side effects.
Who May Qualify for a Blindness Claim Review
You may qualify if:
- you used a GLP-1 drug, AND
- you experienced sudden vision loss, AND
- you were diagnosed with NAION or optic nerve ischemia, AND
- vision did not fully recover
➡️ Start here: File a Claim
Related Information
NAION-related blindness is one of the most severe alleged GLP-1 drug injuries. Because vision loss is often permanent, these claims are evaluated separately and handled in a distinct federal MDL. Early medical and legal review is critical.
➡️ Start your review: File a Claim